|
1
|
Clemens MJ and Elia A: The double-stranded
RNA-dependent protein kinase PKR: Structure and function. J
Interferon Cytokine Res. 17:503–524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
García MA, Gil J, Ventoso I, Guerra S,
Domingo E, Rivas C and Esteban M: Impact of protein kinase PKR in
cell biology: from antiviral to antiproliferative action. Microbiol
Mol Biol. 70:1032–1060. 2006.PubMed/NCBI
|
|
3
|
Murad JM, de Souza LR and De Lucca FL: PKR
activation by a non-coding RNA expressed in lymphocytes of mice
bearing B16 melanoma. Blood Cells Mol Dis. 37:128–133. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Watanabe MAE, Souza LR, Murad JM and De
Lucca FL: Activation of the RNA dependent protein kinase (PKR) of
lymphocytes by regulatory RNAs: implications for immunomodulation
in HIV infection. Curr HIV Res. 3:329–337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel RC and Sen GC: PACT, a protein
activator of the interferon-induced protein kinase, PKR. EMBO J.
17:4379–4390. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh M and Patel RC: Increased
interaction between PACT molecules in response to stress signals is
required for PKR activation. J Cell Biochem. 113:2754–2764. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Williams BR: PKR: a sentinel kinase for
cellular stress. Oncogene. 18:6112–6120. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marchal JA, Lopez GJ, Peran M, Comino A,
Delgado JR, García-García JA, Conde V, Aranda FM, Rivas C, Esteban
M and Garcia MA: The impact of PKR activation: from
neurodeggeneration to cancer. FASEB J. 28:1965–1974. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murad JM, Tone LG, Souza LR and De Lucca
FL: A point mutation in the RNA-binding domain I results in
decrease of PKR activation in acute lymphoblastic leukemia. Blood
Cells Mol Dis. 34:1–5. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Delgado-André N and De Lucca FL: Knockdown
of PKR expression by RNAi reduces pulmonary metastatic potential of
B16-F10 melanoma cells in mice: possible role of NF-kappaB. Cancer
Lett. 258:118–125. 2007.PubMed/NCBI
|
|
11
|
Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao
D, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu DQ: Downregulation of
signal transducer and activator of transcription 3 expression using
vector-based small interfering RNAs suppresses growth of human
prostate tumor in vivo. Clin Cancer Res. 11:6333–6341. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng Y, Wang CC, Choy KW, Du Q, Chen J,
Wang Q, Li L, Chung TK and Tang T: Therapeutic potentials of gene
silencing by RNA interference: principles, challenges, and new
strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Díaz MR and Vivas-Mejia PE: Nanoparticles
as drug delivery systems in cancer medicine: emphasis on
RNAi-containing nanoliposomes. Pharmaceuticals. 6:1361–1380.
2013.PubMed/NCBI
|
|
14
|
Li CH, Parker A, Menocal E, Xiang S,
Borodyansky L and Fruehauf JH: Delivery of RNA interference. Cell
Cycle. 5:2103–2109. 2006. View Article : Google Scholar
|
|
15
|
Sakurai Y, Hatakeyama H, Sato Y, Hyodo M,
Akita H and Harashima H: Gene silencing via RNAi and siRNA
quantification in tumor tissue using MEND, a liposomal siRNA
delivery system. Mol Ther. 21:1195–1203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deharvengt SJ, Gunn JR, Pickett SB and
Korc M: Intratumoral delivery of shRNA targeting cyclin D1
attenuates pancreatic cancer growth. Cancer Gene Ther. 17:325–333.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujita Y, Takeshita F, Kuwano K and Ochiya
T: RNAi therapeutic platforms for lung diseases. Pharmaceuticals.
6:223–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nikitenko NA and Prassolov VS: Non-viral
delivery and therapeutic application of small interfering RNAs.
Acta Naturae. 5:35–53. 2013.PubMed/NCBI
|
|
19
|
Das J, Das S, Paul A, Samadder A,
Bhattacharyya SS and Khuda-Bukhsh AR: Assessment of drug delivery
and anticancer potentials of nanoparticles-loaded siRNA targeting
STAT3 in lung cancer, in vitro and in vivo. Toxicol Lett.
225:454–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paddison PJ, Caudy AA, Bernstein E, Hannon
G and Conklin DS: Short hairpin RNAs (shRNAs) induce
sequence-specific silencing in mammalian cells. Genes Dev.
16:948–958. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar A, Haque J, Lacoste J, Hiscott J and
Williams BR: Double-stranded RNA-dependent protein kinase activates
transcription factor NF-kappa B by phosphorylating I kappa B. Proc
Natl Acad Sci USA. 91:6288–6292. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gil J, Alcamí J and Esteban M: Activation
of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves
the I kappa B kinase complex. Oncogene. 19:1369–1378. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thompson JE, Phillips RJ,
Erdjument-Bromage H, Tempst P and Ghosh S: I kappa B-beta regulates
the persistent response in a biphasic activation of NF-kappa B.
Cell. 80:573–582. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lindgren H, Olsson AR, Pero RW and
Leanderson T: Differential usage of IkappaBalpha and IkappaBbeta in
regulation of apoptosis versus gene expression. Biochem Biophys Res
Commun. 301:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haneji T, Hirashima K, Teramachi J and
Morimoto H: Okadaic acid activates the PKR pathway and induces
apoptosis through PKR stimulation in MG63 osteoblast-like cells.
Int J Oncol. 42:1904–1910. 2013.PubMed/NCBI
|
|
26
|
De Lucca FL, Serrano SV, Souza LR and
Watanabe MA: Activation of RNA-dependent protein kinase and nuclear
factor-kB by regulatory RNA from lipopolysaccharide-stimulated
macrophages: implications for cytokine production. Eur J Pharmacol.
450:85–89. 2002.PubMed/NCBI
|
|
27
|
Watanabe MA, Rodrigues Souza L, Murad JM
and De Lucca FL: Antitumor activity induced by regulatory RNA:
possible role of RNA-dependent protein kinase and nuclear
factor-kappa B. Eur J Pharmacol. 465:205–210. 2003. View Article : Google Scholar : PubMed/NCBI
|
